Rxo (RXO) Receivables (2021 - 2026)

Rxo (RXO) has reported Receivables for 6 consecutive years, with $1.4 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 35.59% year-over-year to $1.4 billion; the trailing twelve-month figure through Jun 2026 stood at $1.4 billion (up 35.59% YoY), and the FY2025 full-year result was $1.3 billion, up 0.64% from the prior year.
• Receivables improved to $1.4 billion in Q2 2026 per RXO's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Receivables topped out at $1.4 billion in Q2 2026 and bottomed at $716.0 million in Q1 2024.
• Historically, Receivables has averaged $1.0 billion across 5 years, with a median of $1.0 billion in 2022.
• The sharpest annual moves came in 2023 and 2024: Receivables declined 22.62% in 2023, then jumped 64.99% in 2024.
• Over 5 years, Receivables stood at $900.0 million in 2022, then declined by 16.22% to $754.0 million in 2023, then surged by 64.99% to $1.2 billion in 2024, then climbed by 0.64% to $1.3 billion in 2025, then climbed by 15.34% to $1.4 billion in 2026.
• According to Business Quant data, Receivables over the past three periods registered $1.4 billion, $1.2 billion, and $1.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.